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HMG-CoA Reductase Inhibitors Reduce MMP-9
Secretion by Macrophages
S. Bellosta, D. Via, M. Canavesi, P. Pfister, R. Fumagalli, R. Paoletti, F. Bernini
Abstract—Macrophages secrete matrix metalloproteinases (MMPs) that may weaken the fibrous cap of atherosclerotic
plaque, predisposing its fissuration. The 92-kDa gelatinase B (MMP-9) has been identified in abdominal aortic
aneurysms and in atherosclerotic tissues. Fluvastatin, through the inhibition of the isoprenoid pathway, inhibits major
processes of atherogenesis in experimental models (smooth muscle cell migration and proliferation and cholesterol
accumulation in macrophages). We studied the effect of fluvastatin on the activity of MMP-9 in mouse and human
macrophages in culture. Conditioned media of cells treated for 24 hours with fluvastatin were analyzed by gelatin
zymography. In mouse macrophages, fluvastatin (5 to 100 mmol/L) significantly inhibited in a dose-dependent manner
MMP-9 activity from 20% to 40% versus control. The drug, at a concentration as low as 5 mmol/L, inhibited MMP-9
activity ('30%) in human monocyte–derived macrophages as well. Phorbol esters (TPA, 50 ng/mL) stimulated MMP-9
activity by 50%, and fluvastatin inhibited this enhanced activity up to 50% in both mouse and human macrophages. The
above results on the secretion of MMP-9 were confirmed by Western blotting and ELISA. The inhibitory effect of
fluvastatin was overcome by the simultaneous addition of exogenous mevalonate (100 mmol/L), a precursor of
isoprenoids. Fluvastatin’s effect was fully reversible, and the drug did not cause any cellular toxicity. The statin did not
block directly the in vitro activation of the secreted protease. Similar data were obtained with simvastatin. Altogether,
our data indicate an inhibition of MMP-9 secretion by the drug. This effect is mediated by the inhibition of synthesis
of mevalonate, a precursor of numerous derivatives essential for several cellular functions. (Arterioscler Thromb Vasc
Biol. 1998;18:1671-1678.)
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Advanced human atherosclerotic plaques are character-ized by a lipid core covered by a fibrous cap composed
of smooth muscle cells (SMCs) and extracellular matrix.1
These lesions also have chronic inflammatory infiltrates of
macrophages and T lymphocytes. Composition and stability
of the plaque, rather than its volume (ie, severity of stenosis),
are the most important determinants of atherosclerosis com-
plications. Plaque disruption with superimposed thrombosis
is the main cause for the acute coronary syndrome of unstable
angina, myocardial infarction, and sudden death.2 Plaque
instability, manifesting as ulceration of the fibrous cap,
plaque rupture, or intraplaque hemorrhage, is characteristic of
plaques with a high lipid content and excess macrophages in
the cap.3,4
Disrupted aortic caps contain fewer SMCs (collagen-
synthesizing cells) and less collagen than intact caps.3,5
Collagen is the main component of fibrous caps responsible
for their tensile strength.5 In addition to the plaque rupture,
the matrix composition participates in several key events in
the development of the atherosclerotic lesion: cell migration
and proliferation, lipoprotein retention, cell adhesion, calci-
fication, thrombosis, coagulation, and apoptosis.6 A wide
range of proteases may be produced at focal sites in plaques.
Macrophages are capable of degrading extracellular matrix
by phagocytosis or by secreting proteolytic enzymes, in
particular a family of metalloproteinases (MMPs) that may
weaken the fibrous cap, predisposing its rupture.7 The 92-kDa
gelatinase B, or MMP-9, is the most prevalent form, ex-
pressed by virtually all activated macrophages, and has been
shown to be more common in atherectomy materials from
unstable angina8 and abdominal aortic aneurysm.9 In addition
to macrophages, SMCs may release MMPs, an event relevant
not only to atherogenesis but especially to the process of
restenosis after angioplasty.7 MMPs play a major role in
restenosis by liberating the SMC from its pericellular matrix
cage as a prerequisite to proliferation and migration.10–14
MMPs are a family of Zn21- and Ca21-dependent enzymes,
which are important in the resorption of extracellular ma-
trixes in both physiological and pathological processes. The
MMPs are secreted as the proenzyme and, once activated, can
completely degrade all extracellular matrix components. The
regulation of these enzymes is very important and occurs at 3
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levels: transcription, activation of latent proenzymes, and inhi-
bition of proteolytic activity.15,16 Interleukin-1, platelet-derived
growth factor, and tumor necrosis factor-a stimulate the synthe-
sis of MMPs; transforming growth factor-b (TGF-b), heparin,
and corticosteroids have an inhibitory effect.7,15 Plasmin is a
potent proenzyme activator of most MMPs, but plasmin-
independent pathways also exist.17,18 In vitro experiments have
shown that phorbol esters (12-0-tetradecanoylphorbol 13-acetate
[TPA]) and lipopolysaccharide can stimulate MMP secretion.19
MMPs are inhibited by a family of naturally occurring specific
inhibitors (tissue inhibitors of metalloproteinases [TIMPs]),
which are secreted multifunctional proteins essential in the
regulation of connective tissue metabolism.
In addition to lipid-lowering therapy, which most probably
affects the size of the atheromatous core, plaque stabilization
could be achieved by a direct inhibition of MMPs in the
arterial wall. Along with TGF-b, corticosteroids, and heparin,
several synthetic inhibitors have been investigated: namely,
tetracyclines, antracyclines, and synthetic peptides. The effi-
cacy of these molecules in therapy, however, is questionable.7
The inhibition of MMP activity also has been investigated in
tumor therapy.
In our laboratory, we demonstrated that fluvastatin, a
hydroxymethylglutaryl coenzyme A (HMG-CoA) reduc-
tase inhibitor (statin), may directly interfere with the major
processes of atherogenesis occurring in the arterial wall.20
SMC migration and proliferation are inhibited by the
drug,21,22 and cholesterol accumulation is prevented in
macrophages23 by reducing modified-LDL endocytosis.24
Interestingly, the inhibitory activity observed in macro-
phages was more pronounced in cholesterol-loaded cells
than in normal cells, suggesting a potential selectivity
of the drug for the foam cells and hence for the athero-
sclerotic lesion.24 All cellular effects mentioned above
are mediated by inhibition of the isoprenoid pathway.
Because the isoprenoid pathway is involved in several
cellular processes25 and macrophage-derived foam cells
constitutively produce MMPs,26 we studied the effect of
fluvastatin on secreted MMP-9 activity in macrophages
in vitro.
Methods
Cell Culture
Mouse peritoneal macrophages (MPMs) were collected by peritoneal
lavage with PBS from mice given a 3-mL intraperitoneal injection of
4% thioglycollate in water. The MPMs were pelleted, washed twice
with serum-free Dulbecco’s modified Eagle’s medium (DMEM;
GIBCO BRL), plated at a density of 33106 cells/35-mm dish, and
allowed to adhere to dishes for 2 hours in DMEM containing 10%
FBS. Then, plates were washed 3 times with DMEM to remove
nonadherent cells and incubated in DMEM containing 10% FBS
until the day of the experiment.
Circulating human monocyte–derived macrophages (HMs) were
isolated from the blood of healthy donors. In brief, blood was
centrifuged, and the buffy coats were underlayered with Ficoll-Paque
(Pharmacia) and centrifuged at 320g for 35 minutes at 25°C. The
monocytes in a broad band below the interface were collected using
a siliconized Pasteur pipette and washed 3 times with cold PBS. The
final pellet was resuspended in serum-free DMEM, and the cells
were plated at a density of 33106 cells in a 35-mm dish. After 2
hours, cell monolayers were washed twice, and the adherent cells
were incubated for 10 to 14 days with DMEM containing 10%
human AB serum and insulin (8 mg/mL).
To generate the conditioned media, cells were incubated for 24
hours at 37°C with DMEM supplemented with 0.2% BSA (Sigma)
and increasing concentrations of fluvastatin in the absence or
presence of phorbol esters (TPA, 50 ng/mL; Sigma). At the end of
the incubation, the conditioned media were collected, and the activity
of secreted MMP-9 was analyzed by zymography. Cellular protein
content was measured according to Lowry et al.26 Cellular toxicity
caused by the drug was assessed using the dimethylthiazaol-
diphenyltetrazolium bromide assay (MTT), which relied on the
ability of viable cells to actively metabolize a tetrazolium dye.27
SDS–Polyacrylamide Gel
Electrophoresis Zymography
Electrophoresis was performed on samples (40 mL for MPMs and 5
mL for HMs of conditioned medium per lane) at 4°C on 7.5%
polyacrylamide gels containing 10% SDS and gelatin (1 mg/mL)
under nonreducing conditions and without boiling. After electro-
phoresis, SDS was removed from gels in 2 washes with 2.5% Triton
X-100 (Sigma) at room temperature. After washes, the gels were
incubated overnight at 37°C with gentle shaking in Tris (50 mmol/L;
pH 7.5) containing NaCl (150 mmol/L), CaCl2 (10 mmol/L), and
ZnCl2 (1 mmol/L) to activate the MMP’s ability to digest the
substrate. For inhibition studies and to confirm the identity of MMPs,
identical gels were incubated in the above buffer containing either
EDTA (20 mmol/L), an inhibitor of MMPs, or PMSF (1 mmol/L), an
inhibitor of serine proteinases. The addition of PMSF did not alter
MMP-9 activity, whereas the treatment with EDTA completely
abolished it (data not shown). At the end of the incubation, the gels
were stained with a solution of 0.1% Coomassie brilliant blue R-250
(Sigma) in 25% methanol and 7% acetic acid. Clear zones against the
blue background indicated the presence of proteinolytic activity. It is
important to note that in this SDS-containing gel, the latent form of
MMP-9, pro–MMP-9, and the activated gelatinase develop gelatino-
lytic activity.28 Therefore, we used the word “activity” to indicate the
total gelatinolytic capacity measured in the conditioned media,
which, in our experimental conditions, is due entirely to the 92-kDa
pro–MMP-9, as assessed by zymography and Western blot analysis
(see experimental data), and after activation by incubation for 2
hours at 37°C with 2 mmol/L APMA (4-aminophenylmercuric
acetate), the propeptide is cleaved to the active form (,90-kDa; data
not shown).
Western Blot Analysis
Aliquots of the conditioned media (40 mL per lane) were run on 10%
polyacrylamide gel containing SDS, under nonreducing conditions.
The proteins were blotted to nitrocellulose membranes (Bio-Rad)
and incubated with a 3% solution of defatted dried milk in PBS
containing 0.1% Tween 20 (PBS-T) to block nonspecific binding.
Then a mouse monoclonal antibody anti–human MMP-9 (clone
6-6B; Calbiochem) diluted in PBS-T was added, and the incubation
continued for 1 hour. This antibody recognizes both the latent (92
kDa) and active (83 kDa) forms of human MMPs-9 under nonre-
ducing conditions but only the latent form under reducing condi-
tions.29 The bound primary antibody was detected using an anti-
mouse secondary antibody conjugated to horseradish peroxidase
(Sigma) and the enhanced chemiluminescence kit (Amersham)
according to the manufacturer’s instructions.
Northern Blot Analysis
RNA was extracted (RNAzol B; Tel-Test Inc) from 33107 to 43107
primary HMs cultured for 12 days and treated with and without
50 mmol/L fluvastatin for 24 hours before harvest. Equal amounts of
total RNA (10 mg) were denatured in 2.2 mol/L formaldehyde, 50%
deionized formamide, and 50 mmol/L MOPS (pH 7.0) at 55°C and
electrophoresed on 1% agarose gels containing 3.4% formaldehyde.
RNA was blot-transferred to GeneScreen Plus membranes using
103 SSC and fixed with UV irradiation. Blots were prehybridized at
68°C for 1 hour. An MMP-9 probe was generated from THP-1 cells
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treated with TPA by reverse transcription–polymerase chain reaction
(PCR) of total RNA using the following primers: sense, 59
TGGGCAGATTCCAAACCTTTGAGGGC 39 and antisense, 59
CCATTCACGTCGTCCTTATGCAAGGG 39. The 1003-bp product
was subcloned into the pCRII vector, and its sequence was verified
as MMP-9. Purified MMP-9 probe (QIAquick, Quiagen, 25 ng)
generated by PCR from the vector or a G3PDH probe (Clontech)
were labeled with [32P]dCTP by random priming and incubated with
the blots in ExpressHyb (Clontech) for 1 hour at 68°C. Blots were
washed (23 SSC; 0.05% SDS) exhaustively at room temperature
and given a final wash at 50°C (0.13 SSC; 0.1% SDS) for 10
minutes. Blots were exposed for autoradiography (X-OMAT AR,
Kodak) and then placed on a Bio-Rad BI screen for quantitative
analysis in the Bio-Rad GS 363 Molecular Imager. After autoradi-
ography to detect MMP-9 mRNA, the blot was stripped by incuba-
tion in 0.01% SDS, 0.013 SSC for 15 minutes at 100°C. The blot
then was reprobed for the G3PDH housekeeping gene.
ELISA
The amount of secreted MMP-9 protein was quantified using the
highly specific Biotrak Matrix MMP-9 ELISA systems (Amersham).
The MMP-9 assay uses 2 antibodies directed against different
epitopes of MMP-9 and does not show detectable cross-reactivity
with MMP-1, -2, and -3 and TIMP-1 and -2 (Amersham). Aliquots
of conditioned media were analyzed as suggested by
the manufacturer.
Statistical Analysis
For quantitation of Western blots and zymograms, densitometric
scanning was performed using a system incorporating a video
camera and a computer analysis package (NIH Image 1.52 image
analysis software). Each experiment was performed at least 3 times
with different preparations of cells. Background was set for each gel,
and each lane was analyzed sequentially. Results were normalized by
cellular protein content and expressed as optical density units. To
validate the method, a linear response of optical density units versus
dilution was obtained for different serial dilutions on 2 separate
samples (data not shown). To standardize conditions between gels,
an aliquot of a standard sample was loaded on each gel, and values
for each band then were normalized to the value of the band of the
reference sample run on the same gel. Data are presented as
mean6SD and analyzed using the Student t test. P values ,0.05
were considered statistically significant
Results
To study the effect of fluvastatin on MMP-9 activity, we
incubated MPMs for 24 hours with increasing concentrations
of the drug. The conditioned media then were collected and
analyzed by gelatin zymography. This technique allows the
visualization of both the active and proenzyme forms of
gelatinases. In our experimental conditions, we observed only
the pro–MMP-9 form (Figure 1). The analysis of the data
obtained in 3 different experiments showed that the addition
of fluvastatin (5 to 100 mmol/L) significantly inhibited in a
dose-dependent manner MMP-9 activity from 20% to 40%
versus control (nontreated cells) (Figure 2A). As expected,
dexamethasone, a corticosteroid known to inhibit MMP gene
transcription,7 suppressed almost completely the enzyme
activity (Figure 2A). In the next series of experiments, we
stimulated MMP activity by incubating the cells with phorbol
ester (TPA, 50 ng/mL), a known enhancer of MMP expres-
sion.7 Treatment with TPA increased MMP-9 activity .50%,
Figure 1. Representative gelatin zymography gel showing the
effect of fluvastatin on MMP-9 activity in MPMs. Mouse macro-
phages were incubated for 24 hours with increasing concentra-
tions of fluvastatin. Conditioned media were collected and
MMP-9 activity measured by gelatin zymography.
Figure 2. Fluvastatin inhibits MMP-9 activity in MPMs. Cells were incubated for 24 hours with increasing concentrations of fluvastatin
in the absence (A) or presence (B) of TPA (50 ng/mL). Data were quantified by densitometric scanning and expressed as the mean6SD
of 3 experiments performed in duplicate. Student t test: A, a indicates P,0.05; b, P,0.01 vs control (nontreated cells). B, a indicates
P,0.01 vs control; b, P,0.01 vs TPA alone.
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and fluvastatin was still effective in inhibiting the enhanced
protease activity by almost 50% (Figure 2B).
Our previous data have shown that fluvastatin may directly
interfere with the major processes of atherogenesis occurring
in the arterial wall20 through the inhibition of the isoprenoid
pathway. Because mevalonate is the precursor of isoprenic
compounds, we postulated that the inhibitory effect of fluva-
statin might be due to a deprivation of mevalonate caused by
the drug. To test this hypothesis, we incubated the cells with
fluvastatin in the presence of exogenous mevalonate
(100 mmol/L). As shown in Figure 3, the addition of
mevalonate fully overcame the inhibitory effect of the statin,
in both the absence and presence of TPA.
To determine whether the inhibitory effect of fluvastatin
was due to an interference with the activation process after
MMP-9 had been secreted, we incubated MPMs with medium
alone. After 24 hours, the conditioned media were collected,
divided in aliquots, and added with increasing concentrations
of the tested drugs. Media then were incubated for 24 more
hours at 37°C, in the absence of cells, and analyzed by gelatin
gel zymography. None of the tested compounds showed any
appreciable effect on MMP-9 activity (data not shown), thus
suggesting that fluvastatin did not interfere with the activa-
tion of the protease.
To exclude a possible drug toxicity as the reason of its
inhibitory effect, MPMs were incubated with fluvastatin (5 to
100 mmol/L) in the absence or presence of TPA (50 ng/mL);
then, cell viability was assessed using the dimethylthiazaol-
diphenyltetrazolium bromide assay. Fluvastatin did not cause
any appreciable cellular toxicity, even at the highest concen-
tration used (100 mmol/L). In another set of experiments,
cells were incubated for 24 hours with medium containing
fluvastatin and then for 24 hours with medium alone. As
shown in Table 1, withdrawal of the drug restored the
capacity of cells to secrete normal amounts of MMP-9. These
data further confirm that fluvastatin is not toxic and that its
inhibitory effect is reversible.
To assess whether fluvastatin was effective also in HMs,
we performed a new series of experiments. As shown in
Figure 4A, the incubation of HMs with increasing concentra-
tions of fluvastatin caused a significant and dose-dependent
reduction of MMP-9 activity in the culture medium. At the
lowest concentration used (0.1 mmol/L), fluvastatin inhibited
MMP-9 activity by 20%, and at the highest (50 mmol/L), by
45% compared with control (Figure 4A). Fluvastatin inhibi-
tory effect was also maintained in the presence of phorbol
ester. The addition of TPA alone (50 ng/mL of medium)
determined a 2.5-fold increase of MMP-9 activity (Figure
4B). This enhancement was dose-dependently blocked
(25% to #60% compared with cells treated with TPA alone)
by increasing amounts of fluvastatin (0.1 to 50 mmol/L;
Figure 4B).
We also performed a Western blot analysis of the media
collected from HMs incubated with fluvastatin. As shown in
Figure 5, the addition of fluvastatin, 5 and 50 mmol/L,
reduced the amount of MMP-9 protein released into the
incubation media by 25% and 50%, respectively. The coin-
cubation with exogenous mevalonate blocked the inhibitory
effect of fluvastatin (Figure 5).
To confirm the above observation obtained with murine
macrophages that the inhibitory effect of fluvastatin was not
due to an interaction of the drug with the protease already
secreted into the media, we performed a different experiment.
HMs were incubated with fluvastatin (5 mmol/L alone or with
100 mmol/L mevalonate) for 24 hours. Media were discarded,
and cells were incubated for an additional 4 hours with
medium alone. At the end of the second incubation, media
were collected and analyzed by zymography. Fluvastatin still
maintained its inhibitory effect on MMP-9 activity, and
mevalonate prevented this effect (Figure 6A). This reduction
in gelatinolytic activity is due to a reduction of the amount of
MMP-9 protein released in the incubation media, as shown by
Western blot analysis (Figure 6B).
We also measured the amount of MMP-9 protein secreted
by HMs with ELISA. As shown in Table 2, the addition of
fluvastatin (5 and 50 mmol/L) inhibited the secretion of
MMP-9 protein, whereas the coincubation with mevalonate
prevented the inhibitory effect.
To determine whether the inhibitory effect we observed
was specific to fluvastatin, we used a different HMG-CoA
reductase inhibitor simvastatin. Data in Table 3 show that the
Figure 3. Mevalonate prevents the inhibitory effect of fluvastatin
on MMP-9 activity in MPMs. Mouse macrophages were incu-
bated for 24 hours with fluvastatin (5 mmol/L) or fluvasta-
tin1mevalonate (100 mmol/L) in the absence or presence of TPA
(50 ng/mL). Conditioned media were collected and MMP-9
activity measured by gelatin zymography. Data are mean6SD of
3 experiments performed in duplicate. Student t test: a indicates
P,0.05 vs control; b, P,0.05 vs fluvastatin alone; c, P,0.05 vs
TPA alone; and d, P,0.05 vs TPA1 fluvastatin.
TABLE 1. Reversibility of the Inhibitory Effect of Fluvastatin
on MMP-9 Activity
Additions, mmol/L
MMP-9 Activity, OD Units6SD
Treatment Washout
No addition 11536108 1139666
Fluvastatin, 5 899638* 1261615
Cells were incubated for 24 hours with medium alone or containing
fluvastatin (5 mmol/L). Media then were collected, and the cells were incubated
for 24 hours in the absence of the drug. MMP-9 activity was measured by
zymography at both time points.
Student t test: *P,0.05 vs control (nontreated cells).
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incubation of mouse macrophages with increasing concentra-
tions of the latter statin caused an inhibition in MMP-9
activity similar to that observed with fluvastatin.
Finally, we evaluated by Northern blot analysis whether
the reduced levels of secreted MMP-9 in fluvastatin-treated
HMs could reflect a reduction in MMP-9 gene expression. As
shown in Figure 7, Northern blots of HMs treated for 24
hours with 50 mmol/L fluvastatin demonstrated no reduction
in the level of MMP-9 gene expression. Instead, an almost
2-fold increase in mRNA levels for MMP-9 was consistently
observed. In contrast, essentially no change was observed in
the levels of the housekeeping gene G3PDH.
Discussion
In this study, we have demonstrated that the in vitro incuba-
tion of mouse macrophages and HMs with fluvastatin or
simvastatin, 2 hypolipidemic and antiatherosclerotic agents,
reduced the amount of MMP-9 secreted, suggesting that the
effect on MMP-9 activity belongs to the statins as a class of
drugs. Cells were treated for 24 hours with increasing
concentrations of fluvastatin, and the data clearly show that
the inhibition of the HMG-CoA reductase enzyme reduces
the amount of protease released into the incubation media.
This effect is reversible and appears to be mediated through
a starvation of mevalonate and its derivatives, because the
coincubation of the cells with fluvastatin and mevalonate
completely overcame the inhibitory effect of the drug. The
experiments show that fluvastatin reduced MMP-9 activity in
gelatin zymography and that the effect of the drug was also
maintained when MMP-9 production was induced by the
coincubation with TPA, a known inducer of MMP gene
transcription. TPA induced a 1.5- to 2.5-fold increase in
Figure 4. Fluvastatin inhibits MMP-9 activity in HMs. HMs were incubated for 24 hours with increasing concentrations of fluvastatin in
the absence (A) or presence (B) of TPA (50 ng/mL). Conditioned media were collected and MMP-9 activity measured by gelatin zymog-
raphy. Data are mean6SD of 3 experiments performed in duplicate. Student t test. A, a indicates P,0.05; b, P,0.005 vs control (non-
treated cells). B, a indicates P,0.01 vs control; b, P,0.01 vs TPA alone.
Figure 5. Representative Western blot analysis of MMP-9 secretion by HMs and quantitation by densitometry. HMs were incubated for
24 hours with fluvastatin (5 or 50 mmol/L) or fluvastatin (5 mmol/L) plus mevalonate (100 mmol/L). Conditioned media were collected
and MMP-9 secretion assessed by Western blot analysis.
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MMP-9 activity in mouse macrophages and HMs, respec-
tively. In these conditions, fluvastatin inhibited MMP-9
activity up to 60% compared with the value obtained in cells
incubated with TPA alone.
The inhibitory effect of fluvastatin on MMP-9 activity
detected by zymography could be the consequence of direct
interference of the drug with the activation process of the
MMPs after this has been secreted. Our data exclude this
hypothesis, because the drug did not have any effect on the
activity of MMP-9 already secreted into the growth media. In
addition, as evaluated by Western blot analysis and ELISA,
fluvastatin reduced the amount of MMP-9 protein released by
the cells, suggesting a direct effect on the secretion process.
The reduced levels of MMP-9 detected in the media by
ELISA, Western blot analysis, and zymography could also be
the result of a fluvastatin-mediated decrease in MMP-9 gene
expression. Our data clearly indicate that this is not the case,
because mRNA levels actually rose in treated cells. This
would suggest a complex mechanism of action of the drug
affecting posttranscriptional processes for MMP-9. A more
detailed examination of these processes, beyond the scope of
this article, will be required to fully understand the mecha-
nism(s) involved.
In addition to TGF-b, corticosteroids, and heparin, several
synthetic inhibitors of MMPs have been investigated: viz,
tetracyclines, antracyclines, and synthetic peptides. The ther-
apeutic efficacy of all of these molecules, however, is
doubtful.7 Inhibition of MMP activity has demonstrated a
direct effect in reducing tumor cells invasion and angiogen-
esis.30–32 The MMP inhibitor GM 6001 was shown to block
SMC migration.33 The synthetic MMP inhibitor BB94 (Bati-
mastat) inhibits gelatinases A and B with IC50 values of 4 and
10 nmol/L, respectively,34 and is able to reduce intimal
thickening after arterial injury by decreasing both SMC
migration and proliferation.35 These data support the conclu-
sion that MMPs play a significant role in regulating intimal
thickening in injured arteries and therefore in atherogenesis.
Fluvastatin and simvastatin are inhibitors of the HMG-
CoA reductase enzyme, a key step in the cholesterol biosyn-
thetic pathway, which synthesizes mevalonate, the precursor
of isoprenoids, a class of compounds involved in several
cellular processes. The treatment with the inhibitors causes
mevalonate starvation inside the cells. This seems to cause
the inhibition of MMP-9 secretion, because the coincubation
with mevalonate completely overcame the reduction of
MMP-9 secretion. Prenylation is a type of stable lipid
modification involving covalent addition of either farnesyl or
geranylgeranyl isoprenoids to conserved cysteine residues at
or near the C-terminus of proteins.36 Known prenylated
proteins include fungal mating factors, nuclear lamins, Ras
and Ras-related GTP-binding proteins, protein kinases, and at
least 1 viral protein.36 Prenylation promotes membrane inter-
actions of most of these proteins and plays a major role in
Figure 6. Mevalonate prevents
the inhibitory effect of fluvasta-
tin on MMP-9 activity and
secretion by HMs. HMs were
incubated with fluvastatin
(5 mmol/L) or fluvasta-
tin1mevalonate (100 mmol/L)
for 24 hours. Media were dis-
carded, and cells were subse-
quently incubated with DMEM
alone. After 4 hours, condi-
tioned media were collected,
MMP-9 activity was measured
by gelatin zymography (A), and
MMP-9 secretion was
assessed by Western blot
analysis (B). Data were ana-
lyzed by densitometry.
TABLE 2. Effect of Fluvastatin on the Secretion of MMP-9
by HMs
Additions, mmol/L
Secreted Proteins, ng/mg Cell
Protein6SD (MMP-9)
No addition 1.5160.08
Fluvastatin, 5 0.8860.07*
Fluvastatin, 50 0.6360.03*
Fluvastatin, 51Mevalonate, 100 1.3960.12
HMs were incubated for 24 hours with medium alone (control) or containing
the indicated concentrations of fluvastatin. Conditioned media were collected,
and the amount of secreted MMP-9 was measured by ELISA as described in
Methods. Data are mean6SD of 2 experiments performed in triplicate.
Student t test: *P,0.01 vs control (nontreated cells).
TABLE 3. Simvastatin Inhibits MMP-9 Activity in
Mouse Macrophages
Additions, mmol/L
MMP-9 Activity,
OD Units6SD
No addition 13506120
Simvastatin, 5 13636203
Simvastatin, 10 1078632*
Simvastatin, 50 1011691*
Dexamethasone, 0.1 1361†
Mouse macrophages were incubated for 24 hours with increasing concen-
trations of simvastatin or dexamethasone (0.1 mmol/L). Conditioned media
were collected, and MMP-9 activity was measured by gelatin zymography. Data
are mean6SD of 2 experiments performed in duplicate.
Student t-test: *P,0.05; †P,0.01 vs control (nontreated cells).
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several protein-protein interactions and in signal transduc-
tion.36 Prenylated proteins of the Rab subgroup, small Ras-
like GTPases in mammalian cells, have an important role in
regulating membrane traffic and exocytic and endocytic
transport processes.37 An inhibition of Rab prenylation causes
a block in protein secretion,38 and the Rab3A is deeply
involved in regulated secretion in neuronal cells.36 Therefore,
it is conceivable that the inhibition of isoprenoids formation
by statins could lead to a reduced MMP-9 secretion by
macrophages, by inhibiting factor(s) essential for the secre-
tion process.
Extrapolation of our in vitro results to the in vivo condition is
difficult, of course. The final net level of proteinase activity
depends on several factors, such as the relative concentrations of
active enzymes and specific inhibitors (ie, TIMPs), and further
studies are required to assess the in vivo relevance of our
observation. Nevertheless, several clinical studies demonstrated
the ability of statins to reduce the incidence of coronary heart
disease,39,40 most probably by increasing the stability of the
atherosclerotic plaque rather than by reducing the stenotic
occlusion.2 This effect may involve, in addition to cholesterol
reduction, a direct effect of these drugs on the arterial wall. We
previously suggested that statins may reduce modified LDL
endocytosis and cholesterol accumulation in macrophages.24 The
inhibitory effect of statins on MMP-9 secretion observed in the
present study suggests an additional potential mechanism for the
stabilizing effect of these drugs on atherosclerotic plaque.41
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